# Quad-Agonist GLP Drugs for Chronic Kidney Disease

Canonical source: https://retacompare.com/research/quad-agonist-glp-drugs-for-chronic-kidney-disease

Therapeutic Applications · 2026-05-02


    Next-generation GLP-1 multi-agonists are being investigated for their potential renoprotective effects in chronic kidney disease (CKD). This analysis explores the therapeutic rationale and ongoing pipeline trials in this emerging area of research.

The big picture

As the pharmaceutical landscape evolves post-Retatrutide, a new generation of multi-agonist therapies is gaining traction, particularly in the context of chronic kidney disease (CKD). Retatrutide, a promising GLP-1 receptor agonist, has opened avenues for exploring the multifaceted roles of incretin-based therapies beyond glycemic control. With CKD affecting millions worldwide and increasing healthcare burdens, the focus is shifting towards agents that not only manage obesity but also confer renal protection. This is particularly relevant given the established links between obesity, metabolic syndrome, and the progression of kidney disease.

How it works

Multi-agonists, such as those targeting GLP-1, GIP, and potentially other pathways, are designed to enhance metabolic regulation through a synergistic mechanism. The GLP-1 receptor is known for its role in insulin secretion, appetite regulation, and gastric emptying. However, emerging evidence suggests that GLP-1 receptor activation may also exert direct renoprotective effects, potentially by reducing inflammation and fibrosis in renal tissues. The combination of GLP-1 with other agonists may amplify these effects, offering a dual benefit for patients with CKD who often face obesity and metabolic challenges. For instance, drugs like Tirzepatide and Semaglutide have shown promise in weight loss and metabolic improvement, suggesting a potential therapeutic angle for CKD management.

Key points at a glance

Multi-agonist therapies may provide dual benefits for CKD and obesity management.

GLP-1 receptor activation is hypothesized to exert renoprotective effects.

Emerging agents include HM15275 (Hanmi) and MariTide (Amgen), among others.

Ongoing clinical trials are assessing the efficacy of these therapies in CKD populations.

Potential mechanisms include reduced inflammation and improved metabolic regulation.

CKD is a growing health concern, necessitating innovative therapeutic strategies.

Research is still in early stages, with many questions remaining unanswered.

Where this fits in the pipeline

Several multi-agonist therapies are currently in various stages of clinical development. For example, HM15275 from Hanmi and MariTide from Amgen are actively being studied for their effects on metabolic parameters and renal outcomes. While specific efficacy data in CKD is still limited, the theoretical basis for their use is supported by early research. Other notable candidates include Mazdutide from Innovent and Survodutide from Boehringer, both of which are also under investigation for their potential benefits in metabolic disease contexts. The landscape remains dynamic, with ongoing trials expected to yield results that may clarify the role of these agents in CKD management.

What it could mean for patients

If the ongoing studies substantiate the renoprotective effects of multi-agonist therapies, this could represent a significant advancement in the treatment landscape for patients with CKD, especially those with concurrent obesity. The potential to address multiple aspects of metabolic dysregulation while protecting renal function could lead to improved clinical outcomes and quality of life. However, it is essential to approach these findings with caution, as the clinical implications will depend on robust evidence from completed trials.

Open questions and what we don't yet know

Despite the promising rationale for multi-agonist therapies in CKD, several questions remain unanswered. The precise mechanisms through which GLP-1 receptor activation influences renal outcomes require further elucidation. Additionally, the long-term safety and efficacy profiles of these agents in CKD populations have yet to be established, raising concerns about potential risks. Regulatory hurdles may also impact the timeline for approval and widespread use of these innovative therapies. As research progresses, these uncertainties will need to be addressed to ensure optimal patient care.

Bottom line

Next-generation GLP-1 multi-agonists hold promise for improving outcomes in chronic kidney disease, but further research is essential to understand their full potential and safety in this context.

This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources